MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414032 | Name: Epanolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epanolol is a beta blocker.

Chemical Structure

Epanolol
Epanolol
CAS#86880-51-5

Theoretical Analysis

MedKoo Cat#: 414032

Name: Epanolol

CAS#: 86880-51-5

Chemical Formula: C20H23N3O4

Exact Mass: 369.1689

Molecular Weight: 369.42

Elemental Analysis: C, 65.03; H, 6.28; N, 11.37; O, 17.32

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Epanolol; Visacor; Epanololum; ICI141,292; ICI-141,292 ICI 141,292
IUPAC/Chemical Name
(+-)-N-(2-((3-(o-Cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-2-(p-hydroxyphenyl)acetamide
InChi Key
YARKMNAWFIMDKV-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H23N3O4/c21-12-16-3-1-2-4-19(16)27-14-18(25)13-22-9-10-23-20(26)11-15-5-7-17(24)8-6-15/h1-8,18,22,24-25H,9-11,13-14H2,(H,23,26)
SMILES Code
O=C(NCCNCC(O)COC1=CC=CC=C1C#N)CC2=CC=C(O)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 369.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Harry JD. Clinical pharmacology of epanolol. Pharmacodynamic aspects. Drugs. 1989;38 Suppl 2:18-27. doi: 10.2165/00003495-198900382-00006. PMID: 2575976. 2: Akhras F, Jackson G. Epanolol. A new once-daily antianginal agent: dose finding and long term efficacy. Drugs. 1989;38 Suppl 2:28-34. doi: 10.2165/00003495-198900382-00007. PMID: 2575977. 3: Withagen AJ, Corbeij HM, Huige MC, Kragten JA, Vermeulen A. Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring. Drugs. 1989;38 Suppl 2:67-9. doi: 10.2165/00003495-198900382-00017. PMID: 2575985. 4: Rydén L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance. J Intern Med. 1992 Jan;231(1):7-11. doi: 10.1111/j.1365-2796.1992.tb00491.x. PMID: 1346268. 5: Blake P, Lewis JA. Epanolol as a model for assessing patient preference in anti-anginal drug therapy. J Clin Pharmacol. 1992 Jan;32(1):85-90. doi: 10.1002/j.1552-4604.1992.tb03793.x. PMID: 1346791. 6: Lefebvre RA, Bogaert MG, Duprez D. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin. Eur J Clin Pharmacol. 1990;38(5):505-7. doi: 10.1007/BF02336692. PMID: 1974206. 7: Blake P. An overview of clinical trial experience with epanolol. Drugs. 1989;38 Suppl 2:81-5. doi: 10.2165/00003495-198900382-00022. PMID: 2575988. 8: Wilcox RG, Bennett T, Macdonald IA, Broughton Pipkin F, Baylis PH. Post- exercise hypotension: the effects of epanolol or atenolol on some hormonal and cardiovascular variables in hypertensive men. Br J Clin Pharmacol. 1987 Aug;24(2):151-62. doi: 10.1111/j.1365-2125.1987.tb03156.x. PMID: 2887189; PMCID: PMC1387744. 9: Readman AS. Comparative multicentre study of the tolerability and efficacy of epanolol versus nifedipine in patients with stable angina pectoris. Drugs. 1989;38 Suppl 2:61-5. doi: 10.2165/00003495-198900382-00015. PMID: 2575983. 10: Jern S. The effects of epanolol on quality of life. Drugs. 1989;38 Suppl 2:71-4. doi: 10.2165/00003495-198900382-00019. PMID: 2575987. 11: Reid W, Ewing DJ, Harry JD, Smith HJ, Neilson JM, Clarke BF. Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol. Br J Clin Pharmacol. 1987 Apr;23(4):383-9. doi: 10.1111/j.1365-2125.1987.tb03066.x. PMID: 2883987; PMCID: PMC1386086. 12: Cockshott ID. Pharmacokinetics of epanolol (ICI 141,292) in healthy young volunteers and comparative data in elderly patients with angina and subjects with renal or hepatic impairment. Drugs. 1989;38 Suppl 2:10-7. doi: 10.2165/00003495-198900382-00005. PMID: 2575975. 13: Clark-Turner N. Comparative multicentre study of the tolerability and efficacy of epanolol versus metoprolol in patients with stable angina pectoris. Drugs. 1989;38 Suppl 2:55-60. doi: 10.2165/00003495-198900382-00014. PMID: 2575982. 14: Venneker EH, Remme WJ, van Hoogenhuyze DC, Krauss XH, Bartels GL, Kruijssen DA, Storm CJ, van Schelven D. Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease. Cardiovasc Drugs Ther. 1994 Apr;8(2):211-9. doi: 10.1007/BF00877329. PMID: 7918133. 15: Hosie J, Scott AK, Petrie JC, Cockshott ID. Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris. Br J Clin Pharmacol. 1990 Mar;29(3):333-7. doi: 10.1111/j.1365-2125.1990.tb03644.x. PMID: 1968755; PMCID: PMC1380134. 16: Riley M, Elborn JS, Khan MM, Stanford CF, Nicholls DP. Comparative effects of epanolol and diltiazem on exercise performance and respiratory gas exchange in angina pectoris. Eur Heart J. 1992 Aug;13(8):1116-22. doi: 10.1093/oxfordjournals.eurheartj.a060323. PMID: 1354616. 17: Van Den Heuvel AF, van der Ent M, van Veldhuisen DJ, Kruijssen DA, Bartels GL, Remme WJ. Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction. J Cardiovasc Pharmacol. 1998 Apr;31(4):506-12. doi: 10.1097/00005344-199804000-00006. PMID: 9554797. 18: Bilski AJ, Hadfield SE, Wale JL. The pharmacology of epanolol (ICI 141292)--a new beta 1-selective adrenoceptor partial agonist. J Cardiovasc Pharmacol. 1988 Aug;12(2):227-32. doi: 10.1097/00005344-198808000-00013. PMID: 2459554. 19: Simon G, Wittig VJ. Antihypertensive and hormonal responses to beta-blockade with intrinsic sympathomimetic activity: pindolol versus epanolol. J Cardiovasc Pharmacol. 1987 Nov;10(5):543-7. doi: 10.1097/00005344-198711000-00008. PMID: 2447403. 20: Vandenbosch H, Piessens J, De Geest H. Effects of a single oral administration of Epanolol on exercise tolerance in patients with stable effort angina pectoris. Acta Cardiol. 1991;46(1):11-25. PMID: 1674394.